% | $
Quotes you view appear here for quick access.

GTx, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • brass_cannon brass_cannon Aug 10, 2009 11:55 AM Flag

    Doubled down, bought the dip

    I'm certainly no expert...but this is what caught my attention in this a.m. earnings release from GTXI:

    Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia (PIN):
    Following our review of results of recent clinical trials evaluating other potential treatments for the prevention of prostate cancer in low risk and medium risk patients, GTx believes that full three year efficacy and safety data can further differentiate toremifene 20 mg, which is being evaluated in high risk men. GTx has therefore decided not to conduct the event-based efficacy analysis which had been anticipated for late summer of 2009 with results to have been available in the fourth quarter. We will instead, following the conclusion of the study in the first quarter of 2010, conduct the final analyses of the clinical trial. GTx plans to announce results of the study and, if successful, the company???s plans to submit a New Drug Application in 2010.

    I'm hopeful that the short delay's intent is to bring home more formidable and convincing results.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Delays in the pharmaceutical world normally mean that something we have not expected, and we have to make it.

      It is not a good sign. Market cap of more than 300 millions are about one time more than it should be.

      PPS destines to fall. How much? I depends on hedge fund who is playing it (for the same reason, the pps may instead increase)

      So, the question is to play risks or safe. BDSI may serve as an example of irrational PPS before and after approval because the ploy of hedge funds

0.62+0.02(+3.33%)Jun 24 4:00 PMEDT